Meta-analysis and time series modeling allow a systematic review of primary HIV-1 drug-resistant prevalence in Latin America and Caribbean

Current HIV Research

Volumn 13, Issue 2, 2015, Pages 125-142

  Campos Coelho, Antonio Victor ^a   De Moura, Ronald Rodrigues ^a   Da Silva, Ronaldo Celerino ^a   Kamada, Anselmo Jiro ^a   Guimarães, Rafael Lima ^a   Brandão, Lucas André Cavalcanti ^a   Coelho, Hemílio Fernandes Campos ^a   Crovella, Sergio ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Drug resistance mutation; HAART; Meta analysis; Primary drug resistance; Systematic review; Time series

Indexed keywords

ANTIVIRAL RESISTANCE; ARTICLE; CARIBBEAN; DISEASE TRANSMISSION; HEALTH PROGRAM; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; META ANALYSIS; MUTATION; PROFESSIONAL STANDARD; PROSTITUTION; SOUTH AND CENTRAL AMERICA; SYSTEMATIC REVIEW; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; PREVALENCE;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARIBBEAN REGION; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; LATIN AMERICA; MUTATION; PREVALENCE; SEX WORKERS;

EID: 84930983012     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162x13999150317155040     Document Type: Article

References (118)

1. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2013: UNAIDS 2013.
2. [2] Beerenwinkel N, Daumer M, Sing T, et al. Estimating HIV Evolutionary Pathways and the Genetic Barrier to Drug Resistance. Journal of Infectious Diseases 2005; 191(11): 1953-60.
3. [3] Shafer RW, Schapiro JM. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS reviews 2008; 10(2): 67.
4. [4] Vella S, Palmisano L. The Global Status of Resistance to Antiretroviral Drugs. Clinical Infectious Diseases 2005; 41(Supplement 4): S239-S46.
5. [5] Schwarzer G. meta: Meta-Analysis with R. R package version 3.7-1. 2014.
6. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing 2014; Viena, Austria. URL http://www.Rproject.org/.
7. [7] DerSimonian R, Kacker R.: Random-effects model for metaanalysis of clinical trials: An update. Contemporary Clinical Trials 2007; 28(2): 105-14.
8. [8] Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. 1959.
9. [9] Box GE, Jenkins GM, Reinsel GC. Time series analysis: forecasting and control. 4th ed. Hoboken, New Jersey: John Wiley & Sons 2013.
10. [10] Dickey DA, Fuller WA. Distribution of the estimators for autoregressive time series with a unit root. Journal of the American statistical association 1979; 74(366a): 427-31.
11. [11] Hyndman RJ, Athanasopoulos G, Razbash S, et al.: Forecast: Forecasting functions for time series and linear models. R package version 5.5. 2014.
12. [12] LJUNG GM, BOX GEP. On a measure of lack of fit in time series models. Biometrika 1978; 65(2): 297-303.
13. [13] Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antiviral therapy 2008; 13 Suppl 2: 25-36.
14. [14] Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2006; 42(11): 1608-18.
15. [15] Vaughan HE, Cane P, Pillay D, Tedder RS. Characterization of HIV type 1 clades in the Caribbean using pol gene sequences. AIDS research and human retroviruses 2003; 19(10): 929-32.
16. [16] Gittens MV, Roth WW, Roach T, et al. The molecular epidemiology and drug resistance determination of HIV type 1 subtype B infection in Barbados. AIDS research and human retroviruses 2003; 19(4): 313-9.
17. [17] Myers JE, Taylor BS, Rojas Fermin RA, et al. Transmitted drug resistance among antiretroviral-naive patients with established HIV type 1 infection in Santo Domingo, Dominican Republic and review of the Latin American and Caribbean literature. AIDS research and human retroviruses 2012; 28(7): 667-74.
18. [18] Cesaire R, Dos Santos G, Abel S, et al. Drug resistance mutations among HIV-1 strains from antiretroviral-naive patients in Martinique, French West Indies. Journal of acquired immune deficiency syndromes 1999; 22(4): 401-5.
19. [19] Hamilton CL, Eyzaguirre LM, Amarakoon, II, et al. Analysis of protease and reverse transcriptase genes of HIV for antiretroviral drug resistance in Jamaican adults. AIDS research and human retroviruses 2012; 28(8): 923-7.
20. [20] Barrow GJ, Hylton-Kong T, Rodriguez N, Yamamura Y, Figueroa JP. HIV-1 drug resistance in treatment-naive chronically infected patients in Jamaica. Antiviral therapy 2013; 18(7): 941-4.
21. [21] Ruibal-Brunet IJ, Cuevas MT, Diaz-Torres H, et al. Genotypic resistance mutations to antiretroviral drugs in HIV-1 B and non-B subtypes from Cuba. Revista panamericana de salud publica = Pan American journal of public health 2001; 10(3): 174-80.
22. [22] Perez L, Alvarez LP, Carmona R, et al. Genotypic resistance to antiretroviral drugs in patients infected with several HIV type 1 genetic forms in Cuba. AIDS research and human retroviruses 2007; 23(3): 407-14.
23. [23] Machado LY, Dubed M, Diaz H, et al. Transmitted HIV type 1 drug resistance in newly diagnosed Cuban patients. AIDS research and human retroviruses 2013; 29(2): 411-4.
24. [24] Jack N, Ravasi G, Schrooten W, et al. Implementing Early- Warning Indicators of HIV Drug Resistance in the Caribbean. Clinical Infectious Diseases 2012; 54(suppl 4): S290-S93.
25. [25] Avila-Rios S, Garcia-Morales C, Garrido-Rodriguez D, et al. National prevalence and trends of HIV transmitted drug resistance in Mexico. PloS one 2011; 6(11): e27812.
26. [26] Lama JR, Sanchez J, Suarez L, et al. Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance. Journal of acquired immune deficiency syndromes 2006; 42(4): 501-5.
27. [27] Soria J, Bull M, Mitchell C, et al. Transmitted HIV resistance to first-line antiretroviral therapy in Lima, Peru. AIDS research and human retroviruses 2012; 28(4): 333-8.
28. [28] DiazGranados CA, Mantilla M, Lenis W. Antiretroviral drug resistance in HIV-infected patients in Colombia. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 2010; 14(4): e298-303.
29. [29] Holguin A, Yebra G, Martin L, et al. Transmitted drugresistance in human immunodeficiency virus-infected adult population in El Salvador, Central America. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2013; 19(12): E523-32.
30. [30] Murillo W, Paz-Bailey G, Morales S, et al. Transmitted drug resistance and type of infection in newly diagnosed HIV-1 individuals in Honduras. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 2010; 49(4): 239-44.
31. [31] Lloyd B, O'Connell RJ, Michael NL, et al. Prevalence of resistance mutations in HIV-1-Infected Hondurans at the beginning of the National Antiretroviral Therapy Program. AIDS research and human retroviruses 2008; 24(4): 529-35.
32. [32] Castillo J, Arteaga G, Mendoza Y, et al. HIV transmitted drug resistance in adult and pediatric populations in Panama. Revista panamericana de salud publica = Pan American journal of public health 2011; 30(6): 649-56.
33. [33] Vercauteren J, Wensing AMJ, van de Vijver DAMC, et al. Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe. Journal of Infectious Diseases 2009; 200(10): 1503-08.
34. [34] Booth CL, Garcia-Diaz AM, Youle MS, et al. Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. Journal of Antimicrobial Chemotherapy 2007; 59(3): 517-24.
35. [35] Afani A, Ayala M, Meyer A, Cabrera R, Acevedo W. Primary resistance to antiretroviral therapy in patients with HIV/AIDS in Chile. Revista medica de Chile 2005; 133(3): 295-301.
36. [36] Rios M, Delgado E, Perez-Alvarez L, et al. Antiretroviral drug resistance and phylogenetic diversity of HIV-1 in Chile. Journal of medical virology 2007; 79(6): 647-56.
37. [37] Acevedo W, Gallardo AM, Galaz J, Afani A, Cortes E. Detection of primary antiretroviral resistance in Chilean patients recently infected with human immunodeficiency virus (HIV). Revista medica de Chile 2007; 135(11): 1406-13.
38. [38] Afani A, Beltran C, Maria Gallardo A, et al. Prevalence of primary antiretroviral resistance among HIV infected patients in Chile. Revista medica de Chile 2010; 138(6): 669-76.
39. [39] Carobene M, Bolcic F, Farias MS, Quarleri J, Avila MM. HIV, HBV, and HCV molecular epidemiology among trans (transvestites, transsexuals, and transgender) sex workers in Argentina. Journal of medical virology 2014; 86(1): 64-70.
40. [40] Pando MA, Gomez-Carrillo M, Vignoles M, et al. Incidence of HIV type 1 infection, antiretroviral drug resistance, and molecular characterization in newly diagnosed individuals in Argentina: A Global Fund Project. AIDS research and human retroviruses 2011; 27(1): 17-23.
41. [41] Andreani G, Espada C, Ceballos A, et al. Detection of HIV- 1 dual infections in highly exposed treated patients. Virology journal 2011; 8: 392.
42. [42] Pando MA, Eyzaguirre LM, Carrion G, et al. High genetic variability of HIV-1 in female sex workers from Argentina. Retrovirology 2007; 4: 58.
43. [43] Kijak GH, Pampuro SE, Avila MM, et al. Resistance profiles to antiretroviral drugs in HIV-1 drug-naive patients in Argentina. Antiviral therapy 2001; 6(1): 71-7.
44. [44] Petroni A, Deluchi G, Pryluka D, et al. Update on primary HIV-1 resistance in Argentina: emergence of mutations conferring high-level resistance to nonnucleoside reverse transcriptase inhibitors in drug-naive patients. Journal of acquired immune deficiency syndromes 2006; 42(4): 506-10.
45. [45] Rodriguez-Rodrigues N, Duran A, Bouzas MB, et al. Increasing trends in primary NNRTI resistance among newly HIV-1-diagnosed individuals in Buenos Aires, Argentina. Journal of the International AIDS Society 2013; 16: 18519.
46. [46] Cecchini DM, Zapiola I, Fernandez Giuliano S, et al. Etravirine resistance mutations in HIV-infected pregnant women. HIV medicine 2013; 14(2): 125-6.
47. [47] Delgado E, Leon-Ponte M, Villahermosa ML, et al. Analysis of HIV type 1 protease and reverse transcriptase sequences from Venezuela for drug resistance-associated mutations and subtype classification: a UNAIDS study. AIDS research and human retroviruses 2001; 17(8): 753-8.
48. [48] Bouchard M, Masquelier B, Moreno M, et al. HIV type 1 drug resistance among naive patients from Venezuela. AIDS research and human retroviruses 2007; 23(3): 482-5.
49. [49] Castillo J, Comegna M, Quijada W, et al. Surveillance of HIV type 1 drug resistance among naive patients from Venezuela. AIDS research and human retroviruses 2009; 25(12): 1329-33.
50. [50] Rangel HR, Garzaro DJ, Torres JR, et al. Prevalence of antiretroviral drug resistance among treatment-naive and treated HIV-infected patients in Venezuela. Memorias do Instituto Oswaldo Cruz 2009; 104(3): 522-5.
51. [51] Escoto-Delgadillo M, Vazquez-Valls E, Ramirez-Rodriguez M, et al. Drug-resistance mutations in antiretroviral-naive patients with established HIV-1 infection in Mexico. HIV medicine 2005; 6(6): 403-9.
52. [52] Nunn AS, da Fonseca EM, Bastos FI, Gruskin S. AIDS Treatment In Brazil: Impacts And Challenges. Health Affairs 2009; 28(4): 1103-13.
53. [53] Brindeiro RM, Diaz RS, Sabino EC, et al. Brazilian Network for HIV Drug Resistance Surveillance (HIVBResNet): a survey of chronically infected individuals. Aids 2003; 17(7): 1063-9.
54. [54] Inocencio LA, Pereira AA, Sucupira MC, et al. Brazilian Network for HIV Drug Resistance Surveillance: a survey of individuals recently diagnosed with HIV. Journal of the International AIDS Society 2009; 12: 20.
55. [55] Tupinambas U, Duani H, Martins AV, Aleixo AW, Greco DB. Transmitted human immunodeficiency virus-1 drug resistance in a cohort of men who have sex with men in Belo Horizonte, Brazil--1996-2012. Memorias do Instituto Oswaldo Cruz 2013; 108(4): 470-5.
56. [56] Dudley DM, Chin EN, Bimber BN, et al. Low-cost ultrawide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance. PloS one 2012; 7(5): e36494.
57. [57] Bermudez-Aza EH, Kerr LR, Kendall C, et al. Antiretroviral drug resistance in a respondent-driven sample of HIV-infected men who have sex with men in Brazil. Journal of acquired immune deficiency syndromes 2011; 57 Suppl 3: S186-92.
58. [58] Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Programa Nacional de DST e Aids. Protocolo Clinico e Diretrizes Terapeuticas para Manejo da Infeccao pelo HIV em Adultos. Brasilia: Ministerio da Saude: Ministerio da Saude, Secretaria de Vigilancia em Saude, Programa Nacional de DST e Aids 2013.
59. [59] de Brito AM, de Castilho EA, Szwarcwald CL. AIDS e infeccao pelo HIV no Brasil: uma epidemia multifacetada. Revista da Sociedade Brasileira de Medicina Tropical 2000; 34(2): 207-17.
60. [60] Nadai Y, Eyzaguirre LM, Sill A, et al. HIV-1 epidemic in the Caribbean is dominated by subtype B. PloS one 2009; 4(3): e4814.
61. [61] Rodrigues R, Scherer LC, Oliveira CM, et al. Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south Brazil. Virus research 2006; 116(1-2): 201-7.
62. [62] Santos AF, Silveira J, Muniz CP, et al. Primary HIV-1 drug resistance in the C-terminal domains of viral reverse transcriptase among drug-naive patients from Southern Brazil. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 2011; 52(4): 373-6.
63. [63] Graf T, Passaes CP, Ferreira LG, et al. HIV-1 genetic diversity and drug resistance among treatment naive patients from Southern Brazil: an association of HIV-1 subtypes with exposure categories. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 2011; 51(3): 186-91.
64. [64] de Medeiros LB, Lacerda HR, Cavalcanti AM, de Albuquerque Mde F. Primary resistance of human immunodeficiency virus type 1 in a reference center in Recife, Pernambuco, Brazil. Memorias do Instituto Oswaldo Cruz 2006; 101(8): 845-9.
65. [65] Cavalcanti AM, Brito AM, Salustiano DM, et al. Primary resistance of HIV to antiretrovirals among individuals recently diagnosed at voluntary counselling and testing centres in the metropolitan region of Recife, Pernambuco. Memorias do Instituto Oswaldo Cruz 2012; 107(4): 450-7.
66. [66] Carobene MG, Rubio AE, Carrillo MG, et al. Differences in Frequencies of Drug Resistance-Associated Mutations in the HIV-1 pol Gene of B Subtype and BF Intersubtype Recombinant Samples. JAIDS Journal of Acquired Immune Deficiency Syndromes 2004; 35(2): 207-09.
67. [67] Grossman Z, Istomin V, Averbuch D, et al. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. Aids 2004; 18(6): 909-15.
68. [68] Soares EA, Santos AF, Sousa TM, et al. Differential drug resistance acquisition in HIV-1 of subtypes B and C. PloS one 2007; 2(8): e730.
69. [69] Cunha RD, Abreu CM, Gonzalez LMF, et al. Differential In Vitro Kinetics of Drug Resistance Mutation Acquisition in HIV-1 RT of Subtypes B and C. PloS one 2012; 7(10): e46622.
70. [70] Dumans AT, Barreto CC, Santos AF, et al. Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure. Infection, genetics and evolution: journal of molecular epidemiology and evolutionary genetics in infectious diseases 2009; 9(1): 62-70.
71. [71] Brigido LF, Ferreira JL, Almeida VC, et al. Southern Brazil HIV type 1 C expansion into the state of Sao Paulo, Brazil. AIDS research and human retroviruses 2011; 27(3): 339-44.
72. [72] Carvalho BC, Cardoso LP, Damasceno S, Stefani MM. Moderate prevalence of transmitted drug resistance and interiorization of HIV type 1 subtype C in the inland North State of Tocantins, Brazil. AIDS research and human retroviruses 2011; 27(10): 1081-7.
73. [73] Passaes CB, Guimaraes ML, Fernandez SL, et al. Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil. Journal of acquired immune deficiency syndromes 2009; 51(1): 7-12.
74. [74] Arruda LB, Fonseca LA, Duarte AJ, Casseb J. Genetic diversity on the integrase region of the pol gene among HIV type 1-infected patients naive for integrase inhibitors in Sao Paulo City, Brazil. AIDS research and human retroviruses 2010; 26(1): 105-7.
75. [75] Teixeira C, de Sa-Filho D, Alkmim W, et al. Short communication: high polymorphism rates in the HR1 and HR2 gp41 and presence of primary resistance-related mutations in HIV type 1 circulating in Brazil: possible impact on enfuvirtide efficacy. AIDS research and human retroviruses 2010; 26(3): 307-11.
76. [76] Araujo LA, Junqueira DM, de Medeiros RM, Matte MC, Almeida SE. Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and CRF31_BC. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 2012; 54(1): 6-10.
77. [77] da Silveira AA, Cardoso LP, Francisco RB, de Araujo Stefani MM. HIV type 1 molecular epidemiology in pol and gp41 genes among naive patients from Mato Grosso do Sul State, central western Brazil. AIDS research and human retroviruses 2012; 28(3): 304-7.
78. [78] Iamarino A, de Melo FL, Braconi CT, Zanotto PM. BF integrase genes of HIV-1 circulating in Sao Paulo, Brazil, with a recurrent recombination region. PloS one 2012; 7(4): e34324.
79. [79] Rangel HR, Garzaro D, Fabbro R, et al. Absence of primary integrase resistance mutations in HIV type 1-infected patients in Venezuela. AIDS research and human retroviruses 2010; 26(8): 923-6.
80. [80] Eshleman SH, Hudelson SE, Bruce R, et al. Analysis of HIV type 1 gp41 sequences in diverse HIV type 1 strains. AIDS research and human retroviruses 2007; 23(12): 1593-8.
81. [81] Eshleman SH, Hudelson SE, Smith P, et al. Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay. AIDS research and human retroviruses 2009; 25(3): 343-5.
82. [82] Murphy G, Parry JV. Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2008; 13(36).
83. [83] Dilernia DA, Gomez AM, Lourtau L, et al. HIV type 1 genetic diversity surveillance among newly diagnosed individuals from 2003 to 2005 in Buenos Aires, Argentina. AIDS research and human retroviruses 2007; 23(10): 1201-7.
84. [84] Avila-Rios S, Mejia-Villatoro CR, Garcia-Morales C, et al. Prevalence and patterns of HIV transmitted drug resistance in Guatemala. Revista panamericana de salud publica = Pan American journal of public health 2011; 30(6): 641-8.
85. [85] Valle-Bahena OM, Ramos-Jimenez J, Ortiz-Lopez R, et al. Frequency of protease and reverse transcriptase drug resistance mutations in naive HIV-infected patients. Archives of medical research 2006; 37(8): 1022-7.
86. [86] Viani RM, Hsia K, Hubbard P, et al. Prevalence of primary HIV-1 drug resistance in pregnant women and in newly diagnosed adults at Tijuana General Hospital, Baja California, Mexico. International journal of STD & AIDS 2007; 18(4): 235-8.
87. [87] Brindeiro R, Vanderborght B, Caride E, et al. Sequence diversity of the reverse transcriptase of human immunodeficiency virus type 1 from untreated Brazilian individuals. Antimicrobial agents and chemotherapy 1999; 43(7): 1674-80.
88. [88] Pilcher CD, Perkins MD, Fiscus SA, et al. Genotypic resistance and the treatment of HIV-1 infection in Espirito Santo, Brazil. The Journal of infectious diseases 1999; 179(5): 1259-63.
89. [89] Dumans AT, Soares MA, Pieniazek D, et al. Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naive human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil. Antimicrobial agents and chemotherapy 2002; 46(9): 3075-9.
90. [90] Barreto CC, Nishyia A, Araujo LV, et al. Trends in antiretroviral drug resistance and clade distributions among HIV-1--infected blood donors in Sao Paulo, Brazil. Journal of acquired immune deficiency syndromes 2006; 41(3): 338-41.
91. [91] Maia Teixeira SL, Bastos FI, Hacker MA, Guimaraes ML, Morgado MG. Trends in drug resistance mutations in antiretroviral-naive intravenous drug users of Rio de Janeiro. Journal of medical virology 2006; 78(6): 764-9.
92. [92] Varella RB, Ferreira SB, de Castro MB, Zalis MG, Tavares MD.: Human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns among treatmentnaive patients in different stages of infection in Rio de Janeiro, Brazil. Journal of medical virology 2007; 79(8): 1033-9.
93. [93] Pires IL, Soares MA, Speranza FA, et al. Prevalence of human immunodeficiency virus drug resistance mutations and subtypes in drug-naive, infected individuals in the army health service of Rio de Janeiro, Brazil. Journal of clinical microbiology 2004; 42(1): 426-30.
94. [94] El-Far F, Medeiros EA, Gasparoto CT, Diaz RS. Antiretroviral drug resistance among patients with human immunodeficiency virus who act as sources or potential sources in occupational accidents involving healthcare workers. Infection control and hospital epidemiology: the official journal of the Society of Hospital Epidemiologists of America 2005; 26(9): 782-8.
95. [95] Soares MA, De Oliveira T, Brindeiro RM, et al. A specific subtype C of human immunodeficiency virus type 1 circulates in Brazil. Aids 2003; 17(1): 11-21.
96. [96] Eyer-Silva WA, Morgado MG. A genotyping study of human immunodeficiency virus type-1 drug resistance in a small Brazilian municipality. Memorias do Instituto Oswaldo Cruz 2005; 100(8): 869-73.
97. [97] Soares EA, Martinez AM, Souza TM, et al. HIV-1 subtype C dissemination in southern Brazil. Aids 2005; 19 Suppl 4: S81-6.
98. [98] Gonsalez CR, Alcalde R, Nishiya A, et al. Drug resistance among chronic HIV-1-infected patients naive for use of anti-retroviral therapy in Sao Paulo city. Virus research 2007; 129(2): 87-90.
99. [99] Cardoso LP, Pereira GA, Viegas AA, Schmaltz LE, Stefani MM. HIV-1 primary and secondary antiretroviral drug resistance and genetic diversity among pregnant women from central Brazil. Journal of medical virology 2010; 82(3): 351-7.
100. [100] Diaz RS, Vasconcelos L, Hayden RL, et al. Similar efficacy of lopinavir/ritonavir-containing regimens among clades B and F HIV-1-Infected individuals in Brazil. Journal of acquired immune deficiency syndromes 2008; 47(3): 399-401.
101. [101] Brigido LF, Nunes CC, Oliveira CM, et al. HIV type 1 subtype C and CB Pol recombinants prevail at the cities with the highest AIDS prevalence rate in Brazil. AIDS research and human retroviruses 2007; 23(12): 1579-86.
102. [102] Eyer-Silva WA, Couto-Fernandez JC, Silva-de-Jesus C, Morgado MG. Prevalence of HIV type 1 drug resistance mutations in treatment-naive and experienced patients from resource-limited settings with universal access to antiretroviral therapy: a survey in two small Brazilian cities. Memorias do Instituto Oswaldo Cruz 2008; 103(2): 143-9.
103. [103] Brigido LF, Franco HM, Custodio RM, et al. Molecular characteristics of HIV type 1 circulating in Sao Paulo, Brazil. AIDS research and human retroviruses 2005; 21(7): 673-82.
104. [104] Ferreira JL, Thomaz M, Rodrigues R, et al. Molecular characterisation of newly identified HIV-1 infections in Curitiba, Brazil: preponderance of clade C among males with recent infections. Memorias do Instituto Oswaldo Cruz 2008; 103(8): 800-8.
105. [105] Velasco-de-Castro CA, Grinsztejn B, Veloso VG, et al. HIV-1 diversity and drug resistance mutations among people seeking HIV diagnosis in voluntary counseling and testing sites in Rio de Janeiro, Brazil. PloS one 2014; 9(1): e87622.
106. [106] Pilotto JH, Grinsztejn B, Veloso VG, et al. Moderate prevalence of transmitted drug resistance mutations among antiretroviral-naive HIV-infected pregnant women in Rio de Janeiro, Brazil. AIDS research and human retroviruses 2013; 29(4): 681-6.
107. [107] Pfrimer IA, Bizinoto MC, Brandao NA, et al. Intermediate levels of transmitted antiretroviral drug resistance in Midwestern Brazil. AIDS research and human retroviruses 2013; 29(2): 205-6.
108. [108] de Medeiros RM, Junqueira DM, Matte MC, et al. Cocirculation HIV-1 subtypes B, C, and CRF31_BC in a drugnaive population from Southernmost Brazil: analysis of primary resistance mutations. Journal of medical virology 2011; 83(10): 1682-8.
109. [109] de Sa-Filho DJ, Ambar RF, Duarte NB, et al. HIV type 1 diversity from newly diagnosed patients in Santos metropolitan area/Brazil. AIDS research and human retroviruses 2009; 25(9): 925-9.
110. [110] Sprinz E, Netto EM, Patelli M, et al. Primary antiretroviral drug resistance among HIV type 1-infected individuals in Brazil. AIDS research and human retroviruses 2009; 25(9): 861-7.
111. [111] Cardoso LP, Queiroz BB, Stefani MM. HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naive patients from Central West Brazil. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 2009; 46(2): 134-9.
112. [112] Ferreira JL, Rodrigues R, Lanca AM, et al. Transmitted Drug Resistance among People Living with HIV/Aids at Major Cities of Sao Paulo State, Brazil. Advances in virology 2013; 2013: 878237.
113. [113] Ferreira AS, Cardoso LP, Stefani MM. Moderate prevalence of transmitted drug resistance and high HIV-1 genetic diversity in patients from Mato Grosso State, Central Western Brazil. Journal of medical virology 2011; 83(8): 1301-7.
114. [114] Reis MN, de Alcantara KC, Cardoso LP, Stefani MM. Polymorphisms in the HIV-1 gp41 env gene, natural resistance to enfuvirtide (T-20) and pol resistance among pregnant Brazilian women. Journal of medical virology 2014; 86(1): 8-17.
115. [115] Gaspareto KV, Mello FM, Dias JR, et al. Genetic diversity and primary resistance among HIV-1-positive patients from Maringa, Parana, Brazil. Revista do Instituto de Medicina Tropical de Sao Paulo 2012; 54(4): 207-13.
116. [116] Prellwitz IM, Alves BM, Ikeda ML, et al. HIV behind bars: human immunodeficiency virus cluster analysis and drug resistance in a reference correctional unit from southern Brazil. PloS one 2013; 8(7): e69033.
117. [117] da Costa ZB, de Lima YA, Martelli CM, Stefani MM. Transmitted HIV resistance among pregnant young women infected with HIV-1 in Brazil. AIDS patient care and STDs 2013; 27(8): 439-41.
118. [118] Sanabani SS, Pastena ER, da Costa AC, et al. Characterization of partial and near full-length genomes of HIV-1 strains sampled from recently infected individuals in Sao Paulo, Brazil. PloS one 2011; 6(10): e25869.